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Background: Long-term administration of low-dose aspirin (LDA) is associated with a greater risk of adverse events,
including gastroduodenal ulcers. The purpose of this study was to identify the risk factors for and assess the role of
medication use in the development of peptic ulcer disease in Japanese patients with no history of peptic ulcers.
Methods: Consecutive outpatients receiving LDA (75 mg/day) who underwent esophagogastroduodenoscopy
between January and December 2010 were enrolled. Clinical parameters, peptic ulcer history, concomitant drugs,
the presence of Helicobacter pylori infection, reason for endoscopy, and endoscopic findings were analysed.
Results: Of 226 total patients, 14 (6.2%) were endoscopically diagnosed with peptic ulcer. Age, sex, current
smoking status, current alcohol consumption, endoscopic gastric mucosal atrophy, and abdominal symptoms
were not significantly associated with peptic ulcers. Diabetes mellitus was more frequent (42.9% vs. 16.5%; P = 0.024) in
patients with peptic ulcers than in those without peptic ulcers. Using multiple logistic regression analysis, co-treatment
with anticoagulants or proton pump inhibitors (PPIs) was significantly associated with increased and decreased risk for
peptic ulcer, respectively (odds ratio [OR], 5.88; 95% confidence interval [CI], 1.19− 28.99; P = 0.03 and OR, 0.13; 95% CI,
0.02 − 0.73; P = 0.02, respectively). Co-treatment with additional antiplatelet agents, H2-receptor antagonists, angiotensin
II Type 1 receptor blockers, angiotensin-converting enzyme inhibitor, 3-hydroxy-3-methylglutaryl-CoA reductase
inhibitor, or nonsteroidal anti-inflammatory drugs was not associated with peptic ulcer development.
Conclusion: The use of PPIs reduces the risk of developing gastric or duodenal ulcers in Japanese patients taking
LDA without pre-existing gastroduodenal ulcers. However, this risk is significantly increased in both patients ingesting
anticoagulants and patients with diabetes. These results may help identify patients who require intensive prophylaxis
against aspirin-induced peptic ulcers.
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The use of low-dose aspirin (LDA; 75 − 325 mg daily)
contributes to the prevention of thrombi and emboli
in patients suffering from ischemic heart disease or
ischemic cerebrovascular disease [1]. However, LDA has
been shown to cause gastrointestinal damage [2] and
be associated with increased risk of gastroduodenal
ulcers and their potentially fatal complications (e.g.,
gastrointestinal bleeding and perforation) [3]. In case-* Correspondence: msasaki@aichi-med-u.ac.jp
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reproduction in any medium, provided the orcontrol studies, the odd ratios (ORs) of bleeding are in
the range of 2.4 − 7.7 [4,5], which is similar to that seen
in regular users of nonsteroidal anti-inflammatory drugs
(NSAIDs) [6]. The mortality attributable to the use of
NSAIDs or LDA is approximately 20 − 25 cases per
million people, and one-third of these cases are attrib-
utable to LDA [7].
The identified risk factors for ulcer bleeding with
aspirin use are history of ulcer bleeding; aspirin dose;
advanced age (>70 years); concomitant use of NSAIDs
or anti-coagulants; use of dual anti-platelet therapy;
Helicobacter pylori (H. pylori) infection; and history oftral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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inhibitors (PPIs) are used to decrease LDA-associated
gastroduodenal mucosal and NSAID-induced injuries
[9-11]. In Japan, since 2011, treatment with half-dose
PPI (lansoprazole 15 mg/day) has been permitted as a
medical service under health insurance for the prevention
of NSAID- or LDA-induced peptic ulcers in patients in
the high-risk group who have a history of peptic ulcers.
Yeomans et al. [12] alleged that the use of esomeprazole
20 mg reduces the risk of developing LDA-associated
gastric and/or duodenal ulcers in elderly patients without
pre-existing gastroduodenal ulcers. However, there are
few reports in which the use of PPIs reduced the risk
of LDA-associated peptic ulcers in patients without
pre-existing peptic ulcers. The aim of this retrospective
study is clarify the effect of PPIs and other drugs on peptic
ulcer development in Japanese patients who are taking
LDA but do not have pre-existing peptic ulcers.Methods
This was a retrospective observation study performed
at Aichi Medical University Hospital between January
and December 2010. This study was approved by the
ethical committee of Aichi Medical University. All endo-
scopic examinations were recorded digitally. Consecutive
outpatients taking LDA (75 mg/day) for >3 months were
enrolled, and the endoscopic findings were blindly eval-
uated by 1 experienced endoscopist. We defined an ulcer
as a mucosal deficit > 5 mm in diameter. The exclusion
criterion was a history of gastrectomy.
We recorded the following data from patient medical
records: clinical characteristics, including sex, age, and
smoking and drinking habits; underlying disease (hyper-
tension, hyperlipidemia, ischemic heart disease, diabetes
mellitus, cerebrovascular disease, collagen disease); peptic
ulcer history; concomitant drugs (gastric agents, anticoag-
ulants [warfarin potassium]); antiplatelet drugs (ticlopidine
HCL, clopidogrel sulphate, cilostazol); NSAIDs; corticoste-
roids; antihypertensives; antihyperlipidemics; the presence
of H. pylori infection; reason for endoscopy (abdominal
symptoms [epigastric pain, heartburn, dysphagia, anorexia,
nausea] or bleeding signs [anaemia, hematemesis, tarry
stool]); and endoscopic findings.
H. pylori infection was determined using a rapid urease
test, culture, or histology. The criterion of no pre-existing
gastroduodenal ulcers was defined as no peptic ulcer
history by medical record and no evidence of peptic
ulcer scarring on endoscopy. Gastric mucosal atrophy
was endoscopically scored on a 6-grade scale (C1, C2,
C3, O1, O2, and O3; C, closed; O, open) according to
Kimura and Takemoto’s classification [13]. The presence
of gastric mucosal atrophy was defined as an endoscopic
score of C3–O3.Results
A total of 226 patients (mean age, 72.0 years) were
enrolled, and 14 patients (6.2%) were endoscopically
diagnosed with peptic ulcers. Patient demographic and
clinical characteristics are shown in Table 1. Ulcer
lesions were found in the stomach of 12 patients (5.3%)
and in the duodenum of 2 patients (0.9%). Age, sex,
current smoking status, current alcohol consumption,
endoscopic gastric mucosal atrophy, and abdominal
symptoms were not significantly associated with peptic
ulcers. As the underlying disease of aspirin users, diabetes
mellitus was more frequent (42.9% vs. 16.5%, P = 0.024) in
patients with peptic ulcers than in those without peptic
ulcers (Table 1).
On univariate analysis, the percentage of patients
with peptic ulcers who were taking anticoagulants was
significantly higher (28.6% vs. 9.0%; OR, 3.53; 95% CI,
1.20 − 10.36). Co-treatment with anticoagulants was sig-
nificantly associated with peptic ulcers in the multiple
logistic regression analysis after adjustment for age and
sex (OR, 5.88; 95% CI, 1.19 − 28.99). The percentage of
patients taking PPIs was significantly lower in the
group with peptic ulcers than in the group without
peptic ulcers (14.3% vs. 42.0%; adjusted OR, 0.13; 95%
CI, 0.02 − 0.73. Co-treatment with additional antiplatelets,
H2-receptor antagonists (H2RA), angiotensin II Type 1 re-
ceptor blockers, angiotensin-converting enzyme inhibitor,
3-hydroxy-3-methylglutaryl-CoA reductase inhibitor, and
NSAIDs was not associated with peptic ulcers (Table 2).
Discussion
To our knowledge, there is only 1 prospective trial in-
vestigating the risk of primary peptic ulcer development
in patients taking LDA with or without concomitant acid
suppressive therapy [12]. In that trial, only patients
without pre-existing peptic ulcers were enrolled, and
26-week treatment with esomeprazole at 20 mg once
daily significantly reduced the risk of peptic ulcer
formation in patients taking LDA for the secondary
prevention of cardiovascular events. However, the patients
were ≥60 years of age and tested negative for H. pylori.
In our study, we retrospectively investigated the asso-
ciation between peptic ulcers and clinical parameters,
including a combination of medicine, in a restricted
population of patients without pre-existing peptic ulcers.
In a Japanese epidemiologic study, there was minimal
biological interaction between H. pylori infection and
NSAIDs with respect to bleeding [5], and NSAIDs and
H. pylori infection seem to be independent risk factors
for peptic ulcers and bleeding. In this retrospective
study, H. pylori infection was observed in only 8 patients;
therefore, we could not investigate the influence of
H. pylori infection on peptic ulcer development. In the
present study, previous eradication therapy was not
Table 1 Demographic and clinical characteristics of patients with and without peptic ulcer
Patients without ulcer Patients with ulcer
Variable n = 212 n = 14 P value
Mean age, years (SD) 71.9 (9.5) 72.6 (7.2) 0.785 *
≥70 years old (%) 124 (58.5) 11 (78.6) 0.168 **
Male sex (%) 128 (60.4) 12 (85.7) 0.086 **
Current smoker (%) 30 (14.2) 1 (7.1) 0.699 **
Current alcohol drinker (%) 20 (9.4) 1 (7.1) 1.000 **
Gastric mucosal atrophy (%) 98 (46.2) 6 (42.9) 1.000 **
Hypertension (%) 143 (67.5) 9 (64.3) 0.776 **
Ischemic heart disease (%) 94 (44.3) 4 (28.6) 0.281 **
Other cardiac disease (%) 20 (9.4) 1 (7.1) 1.000 **
Cerebrovascular disease (%) 30 (14.2) 0 (0.0) 0.225 **
Diabetes mellitus (%) 35 (16.5) 6 (42.9) 0.024 **
Hyperlipidemia (%) 102 (48.1) 6 (42.9) 0.787 **
Chronic renal failure (%) 14 (48.1) 2 (14.3) 0.260 **
Abdominal symptoms (%) 80 (37.7) 8 (57.1) 0.166 **
*Unpaired t test, **Fisher’s exact test.
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patients were found to have endoscopic gastric mucosal
atrophy. This result suggests that the H. pylori infection
rate is high. Previous studies have documented a risk of
peptic ulcer complications for upper gastrointestinal
bleeding [8,14-16]; however, there were only a few reports
on patients without pre-existing peptic ulcers. In the
present study, diabetes mellitus was more frequently
observed in patients with ulcers than in those without
ulcers as the causative disease of peptic ulcer in aspirin
users without a history of peptic ulcers. The present
results are consistent with those of former reports.Table 2 Association of peptic ulcer and use of other medicine
Case without ulcer Case
Medicine n = 212 (%) n =
Anticoagulanta 19 (9.0) 4
Other antiplateletb 49 (23.1) 1
PPIc 89 (42.0) 2
H2RAd 36 (17.0) 1
Ca-blockere 67 (31.6) 4
ARBf 99 (46.7) 5
ACE inhibitorg 17 (8.0) 1
HMG-Co A redactase inhibitorh 94 (44.3) 6
NSAIDi 9 (4.3) 2
OR, odds ratio; CI, confidence interval; PPI, proton pump inhibitor; H2RA, H2-recepto
HMG-Co A, 3-hydroxy-3-methyglutaryl coenzyme A, NSAID, non-steroidal anti-inflam
*Univariate analysis; ** Multivariate analysis adjusted for age and sex.
aWarfarin 1 − 5 mg/day, bTiclopidine 100 or 200 mg/day, clopidogrel 75 mg/day, cil
day, rabeprazole 10 mg/day, dFamotidine 10 or 20 or 40 mg/day, ranitidine 150 mg
day, amlodipine 2.5 or 5 mg/day, fCandesartan 4 or 8 mg/day, telmisartan 40 mg/d
atorvastatin 10 mg/day, iLoxoprofen 60 or 120 or 180 mg/day, selecoxib 100 mg/daConcomitant anti-coagulant therapy is significantly associ-
ated with an increased risk of peptic ulcers. However,
anticoagulants have not been convincingly shown to
increase the risk of ulcer development. In the present
study, of the 23 patients taking concomitant anticoag-
ulants, 9 (39%) had a bleeding rate that was higher
than 40 (20%) of the 203 patients who were not taking
concomitant anticoagulants. These results suggest that
anticoagulants might increase the risk of LDA-induced
ulcer bleeding.
In the present study, co-treatment with PPIs significantly
reduced the risk of peptic ulcers. This result is consistents among patients taking low-dose aspirin
with ulcer Adjusted OR
14 (%) OR (95% CI)* (95% CI)**
(28.6) 4.06 (1.16 − 14.21) 5.88 (1.19 − 28.99)
(7.1) 0.26 (0.03 − 2.01) 0.20 (0.02 − 1.83)
(14.3) 0.23 (0.05 − 1.05) 0.13 (0.02 − 0.73)
(7.1) 0.38 (0.05 − 2.97) 0.35 (0.04 − 3.20)
(28.6) 0.87 (0.26 − 2.86) 1.27 (0.32 − 5.14)
(35.7) 0.63 (0.21 − 1.96) 0.45 (0.12 − 1.65)
(7.1) 0.88 (0.11 − 7.16) 0.39 (0.05 − 4.34)
(42.9) 0.94 (0.32 − 2.81) 2.09 (0.53 − 8.29)
(14.3) 3.76 (0.73 − 19.36) 6.48 (0.75 − 56.41)
r antagonist; ARB, AT1-receptor blocker; ACE, angiotensin-converting enzyme;
matory drug.
ostazol 200 mg/day, cOmeprazole 10 or 20 mg/day, lansoprazole 15 or 30 mg/
/day, roxatidine 150 mg/day, lafutidine 10 mg/day, eNifedipine 20 or 40 mg/
ay, olmesartan 20 mg/day, gImidapril 5 mg/day, hPravastatin 10 mg/day,
y, naproxen 300 mg/day.
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randomized, placebo-controlled trial. Moreover, in our
study, there were 7 bleeding cases (6 without PPI, 1
with PPI) in 6 patients with gastric ulcers and 1 patient
with a duodenal ulcer. Of the 135 patients who were
not taking PPIs, 6 (4.4%) had gastroduodenal bleeding,
a rate that was higher than that for placebo (1.0%) in
the study by Yeomans et al. The difference may be the
influence of H. pylori infection; however, our data are
very limited and a further study is necessary to verify
our findings. LDA was associated with the risk of gas-
troduodenal ulcers and their potentially fatal complications
(e.g., gastrointestinal bleeding), even in patients without
pre-existing peptic ulcers.
The identified risk factors for gastrointestinal ulcer
with LDA use are as follows: a history of ulcer; aspirin
dose; advanced age (>70 years); concomitant use of
NSAIDs; use of dual anti-platelet therapy; H. pylori
infection; and history of alcohol abuse, diabetes, or
renal failure [6,8]. PPIs and H2-RA are used to decrease
LDA-associated gastroduodenal mucosal lesions [9-11,17].
However, these studies included patients with a peptic
ulcer history (the highest risk factor) and did not analyzed
only patients without a peptic ulcer history. In patients
without a peptic ulcer history, the risk factors have not
yet been clarified, although they may be the same. In
this study, advanced age; concomitant use of NSAIDs;
use of dual anti-platelet therapy; H. pylori infection;
and a history of alcohol abuse, or renal failure were not
identified risk factors. Additionally, H2RA was not an
identified protective factor. This outcome may have
occurred as a result of our study being insufficiently
powered.
Because of its retrospective design, the limitations of
the present study include the absence of a diagnosis of
H. pylori infection and ambiguous clinical information,
especially with regard to medication history, including
NSAIDs. In our clinic, information about anti-platelets
and anti-coagulants is clear because these medications
were carefully recorded habitually prior to endoscopic
examinations. Because this study included only those
patients without a history of peptic ulcers, a large-scale
and prospective study will be necessary to clarify the risk
or protective factors of LDA-associated gastroduodenal
mucosal lesions.
Conclusions
PPI therapy reduces the risk of developing gastric or
duodenal ulcers in patients without pre-existing gas-
troduodenal ulcers. However, this risk is significantly
increased in both patients who are ingesting anticoag-
ulants and patients with diabetes. These results may
help identify patients who require intensive prophy-
laxis against aspirin-induced ulcers. Further studies arenecessary to clarify the indication of treatment with
PPIs for preventing NSAID- or LDA-induced peptic
ulcers in patients without a history of peptic ulcers.
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